Wararka
-
Warbixin Xeer Cusub
1. Xeerarka cusub ee Diiwaangelinta FDA ee alaabta la isku qurxiyo ee Maraykanka iyada oo aan la helin Diiwaangelinta FDA waa laga mamnuucayaa iibka. Sida ku cad Casriyeynta Xeerka Xeerka Isqurxinta ee 2022, oo uu saxeexay Madaxweyne Biden Diseembar 29, 2022, dhammaan waxyaabaha la isku qurxiyo ee loo dhoofiyo Maraykanka waa inay noqdaan FDA-diiwaan-gal...Sii akhri -
2023 API 88aad Shiinaha
Macluumaad ku saabsan JYMed at 2023 API CHINA 【on-site】 Hoos hoggaanka maareeyaha guud Zhi Qin, Shenzhen JYMed Technology Co., Ltd. (Hadda ka dib loogu yeero JYMed) ayaa ka qaybgalay bandhiggan weyn. JYMed waxay soo bandhigtay alaabo faa'iido leh Semaglutide, Liraglutide, Tirzepatide, O...Sii akhri -
Ku soo dhawoow inaad nagu kulanto bandhigga API ee Qindao China JYMed stock: N4K32
Sii akhri -
JYMed ayaa kula kulmay PCHi
Laba sano oo la filayey ka dib, 2023 Shiinaha International Cosmetics Cosmetics Personal and Home Care Cyrials Exhibition (PCHi) ayaa lagu qabtay Guangzhou Canton Fair Complex Febraayo 15-17, 2023.Sii akhri -
Semeglutide API ee Shenzhen JYMed aqbalay dufcaddii ugu horeysay ee NMPA gudaha oo ka diiwaan gashan US FDA (DMF No. 036009) oo leh xaalad "A".
Bishii Maajo 2022, Shenzhen JYMed Technology Co., Ltd. (oo hadda loo yaqaan JYMed peptide) waxay soo gudbisay codsiga diiwaangelinta semaglutide API Maamulka Cuntada iyo Dawooyinka ee Maraykanka (FDA) (lambarka diiwaangelinta DMF: 036009), Waxay ka gudubtay dib u eegista daacadnimada, iyo heerka hadda i...Sii akhri
